UK Markets closed

DBV Technologies S.A. (DBVT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.3800-0.0600 (-4.17%)
As of 12:46PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.4400
Open1.4100
Bid1.3900 x 1800
Ask1.4000 x 900
Day's range1.3800 - 1.4300
52-week range1.3510 - 6.8800
Volume42,632
Avg. volume670,170
Market cap155.921M
Beta (5Y monthly)2.21
PE ratio (TTM)N/A
EPS (TTM)-1.1260
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.99
  • Globe Newswire

    Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

    AMF REGULATED INFORMATIONMontrouge, France, January 21, 2022 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. As of December 31, 2021, the following assets appeared on the liquidity account: 153,631 DBV Technologies shares;€ 175,542.33. Upon signing the liquidity contract

  • Globe Newswire

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2021

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights12/31/202155,095,762 Total gross of voting rights: 55,095,762 Total net* of voting rights: 54,942,131 * Total net = total number of voting rights attached to shares – shares wi

  • Globe Newswire

    DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference

    Montrouge, France, January 7, 2022 DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference. The fireside chat will be available for on-demand viewing starting Monday, January 10, 2022, at 7:00am ET. A webc